Kiniksa Pharmaceuticals Ltd

Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, Vixarelimab, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Lexington, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Kiniksa Pharmaceuticals reports robust Q2 growth and strategic initiatives

Kiniksa Pharmaceuticals delivered a strong Q2 performance with significant revenue growth driven by ARCALYST sales and strategic initiatives. The company's focus on disease awareness and patient base expansion bodes well for future growth.
While challenges such as managing expenses and addressing operational complexities persist, Kiniksa's solid financial position and market opportunities position it favorably for sustained growth and value creation.
Overall, Kiniksa Pharmaceuticals' Q2 earnings call highlights a mix of strong performance, strategic strengths, operational challenges, and growth opportunities, signaling a dynamic and evolving landscape for the company.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Kiniksa Pharmaceuticals International Plc is a commercial-stage biopharmaceutical company. It engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. The company was founded on April 9, 2024 and is headquartered in London, United Kingdom.

Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA ) Q3 2023 Earnings Conference Call October 31, 2023 8:30 AM ET Company Participants Rachel Frank - Associate Director, IR Sanj Patel - CEO Ross Moat - SVP and CCO Mark Ragosa - SVP and CFO John Paolini - SVP and CMO Conference Call Participants Anupam Rama - JPMorgan Paul Choi - Goldman Sachs David Nierengarten - Wedbush Securities Liisa Bayko - Evercore ISI Operator Good day and thank you for standing by. Welcome to the Kiniksa Pharmaceuticals Third Quarter 2023 Earnings Conference Call.

Kiniksa Pharmaceuticals Ltd (KNSA) Q3 2023 Earnings Call Transcript

– ARCALYST ® (rilonacept) Q3 2023 net product revenue of $64.8 million, representing ~94% year-over-year growth –

Kiniksa Pharmaceuticals Reports Third Quarter 2023 Financial Results and Recent Portfolio Execution

HAMILTON, Bermuda, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 31, 2023 at 8:30 a.m. Eastern Time to report its third quarter 2023 financial results and recent portfolio execution.

Kiniksa Pharmaceuticals to Report Third Quarter 2023 Financial Results on October 31, 2023

Shares of Kiniksa Pharmaceuticals surged after the company reported strong Q2 results and raised the full-year net sales guidance for Arcalyst. The strong growth and improved outlook were driven by the recent sales force expansion. I see Arcalyst as a $600 million to $700 million drug by 2026.

Kiniksa Pharmaceuticals: Arcalyst's Growth Picks Up

Kiniksa saw revenue rise, year over year, by 165%. Its lead therapy is heart drug Arcalyst.

Why Shares of Kiniksa Pharmaceuticals Jumped Tuesday

Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA ) Q2 2023 Q2 2023 Earnings Call Transcript July 25, 2023 8:30 AM ET Company Participants Rachel Frank - Associate Director of Investor Relations Sanj Patel - Chief Executive Officer Ross Moat - Senior VP & Chief Commercial Officer Eben Tessari - Chief Operating Officer Mark Ragosa - Senior VP & CFO John Paolini - Senior VP & Chief Medical Officer Conference Call Participants Anupam Rama - JPMorgan Paul Choi - Goldman Sachs Alexandria Hammond - BofA David Nierengarten - Wedbush Securities Liisa Bayko - Evercore ISI Operator Good day, and thank you for standing by. Welcome to the Kiniksa Pharmaceuticals Second Quarter 2023 Earnings Conference Call.

Kiniksa Pharmaceuticals Ltd (KNSA) Q2 2023 Earnings Call Transcript

– ARCALYST ® (rilonacept) Q2 2023 net product revenue of $54.5 million – – ARCALYST 2023 net product revenue guidance increased to $220 - $230 million, representing ~84% year-over-year growth at the midpoint – – KPL-404 Phase 2 rheumatoid arthritis data expected in 1H 2024 – – Cash reserves now expected to fund operations into at least 2027 – – Conference call and webcast scheduled for 8:30 am ET today –

Kiniksa Pharmaceuticals Reports Second Quarter 2023 Financial Results and Recent Portfolio Execution

Innovations in the drug lineup, including ARCALYST, KPL-404, and Mavrilimumab, showcase Kiniksa's dedication to targeting challenging autoimmune and inflammatory conditions. ARCALYST's net product revenue in Q1 2023 summed to $42.7 million, with a full-year 2023 net product revenue estimate for ARCALYST ranging between $200 million and $215 million. Kiniksa is also evaluating KPL-404 for its potential in rheumatoid arthritis treatment, with Phase 2 clinical trial results anticipated in early 2024.

Kiniksa Pharmaceuticals: Autoimmune Therapy Offers Attractive Prospects At Current Price

HAMILTON, Bermuda, July 17, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 25, 2023 at 8:30 a.m. Eastern Time to report its second quarter 2023 financial results and recent portfolio execution.

Kiniksa Pharmaceuticals to Report Second Quarter 2023 Financial Results on July 25, 2023

Cadre Holding

Evolution Petroleum

While your friendly financial advisor probably won't direct you to this space, small-cap stock picks can be worth your while, so long as you understand the volatility risks and don't unreasonably stretch yourself. To set definitions, small-cap investments refer to companies which feature a market capitalization between $250 million to $2 billion.

3 Small-Cap Stocks That Are Worth the Gamble

Today, we take our first look at a commercial stage biopharma concern called Kiniksa Pharmaceuticals, Ltd. The company is seeing impressive growth from its primary drug asset and has an intriguing pipeline. An investment analysis follows in the paragraphs below.

Kiniksa Pharmaceuticals: A Somewhat Complicated Story

HAMILTON, Bermuda, June 06, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on Tuesday, June 13, 2023 at 8:40 a.m. Pacific Time (11:40 a.m. Eastern Time).

Kiniksa Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA ) Q1 2023 Earnings Conference Call May 2, 2023 8:30 AM ET Company Participants Rachel Frank - Head of Investor Relations Sanj Patel - Chief Executive Officer Ross Moat - Chief Commercial Officer Mark Ragosa - Chief Financial Officer John Paolini - Chief Medical Officer Conference Call Participants Paul Choi - Goldman Sachs Geoff Meacham - Bank of America Operator Good day and thank you for standing by and welcome to the Kiniksa Pharmaceuticals First Quarter 2023 Earnings Conference Call.

Kiniksa Pharmaceuticals, Ltd. (KNSA) Q1 2023 Earnings Call Transcript

– ARCALYST ® (rilonacept) Q1 2023 net product revenue of $42.7 million – – ARCALYST full-year 2023 net product revenue guidance increased to $200 - $215 million, representing ~69% year-over-year growth at the midpoint – – Final cohort of KPL-404 Phase 2 rheumatoid arthritis trial now enrolling patients; data expected in 1H 2024 – – Cash reserves now expected to fund operations into at least 2026 – – Conference call and webcast scheduled for 8:30 am ET today –

Kiniksa Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Portfolio Execution

HAMILTON, Bermuda, May 01, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, May 2, 2023, at 8:30 a.m. Eastern Time to report its first quarter 2023 financial results and recent portfolio execution.

Kiniksa Pharmaceuticals to Report First Quarter 2023 Financial Results on May 2, 2023

AbCellera Biologics

Chimerix

Ocuphire Pharma

Point Biopharma Global

Vaccitech

Vir Biotechnology

While it might be difficult to navigate the equities sector now amid various headwinds, biotech stocks to buy may offer a surprising respite. True, the market presence of the surprise production cuts by the Organization of the Petroleum Exporting Countries (OPEC) and non-member oil-producing nations — known as OPEC+ — along with the Federal Reserve's possible response.

7 Thrilling Biotech Stocks for Aggressive Investors to Buy

Kiniksa Pharmaceuticals, Ltd. (KNSA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.

After Plunging -13.29% in 4 Weeks, Here's Why the Trend Might Reverse for Kiniksa Pharmaceuticals, Ltd. (KNSA)

ARKO

Ichor Hlds

SpartanNash

A-Mark Precious Metals

Cross Country Healthcare

Vertex Energy

While most financial advisors will direct you to a healthy portion of established, large-capitalization enterprises, small-cap stocks to buy provide extra oomph for willing participants. For example, age can be a determining factor in whether smaller, more speculative enterprises are appropriate.

7 Small-Cap Stocks to Buy for Explosive Growth Potential

Core Molding Technologies

TrueBlue

Vipshop Hlds

Enerplus

iTeos Therapeutics, Inc.

Perdoceo Education

While it's always nice to get a discount, with cheap stocks, it may be better to go for enterprises sitting in the sweet spot; that is, publicly traded securities that are cheap but not too cheap where investors might fret about possible value traps. On this list, I'm only going to target (as of the time of writing) equity shares that trade between $10 and $20.

7 Dirt-Cheap Stocks Sitting in the Sweet Spot

Aptevo Therapeutics

Beam Therapeutics

Dynavax Technologies

Biotech stocks almost always have the potential for significant growth over time. Companies in the sector operate in areas including drug development, medical devices, and diagnostics.

The Top 7 Growth Stocks in Biotech

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA ) Q4 2022 Results Conference Call February 28, 2023 8:30 AM ET Company Participants Rachel Frank - Head of Investor Relations Sanj Patel - Chief Executive Officer Ross Moat - Chief Commercial Officer Mark Ragosa - Chief Financial Officer Eben Tessari - Chief Operating Officer John Paolini - Chief Medical Officer Conference Call Participants Anupam Rama - JP Morgan Paul Choi - Goldman Sachs David Nierengarten - Wedbush Geoff Meacham - Bank of America Liisa Bayko - Evercore ISI Operator Good day, and thank you for standing by.

Kiniksa Pharmaceuticals, Ltd. (KNSA) Q4 2022 Earnings Call Transcript

Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 125% and 31.18%, respectively, for the quarter ended December 2022.

Kiniksa Pharmaceuticals, Ltd. (KNSA) Beats Q4 Earnings and Revenue Estimates

– ARCALYST ® (rilonacept) Q4 2022 and full-year 2022 net product revenue of $39.9 million and $122.5 million, respectively –

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Portfolio Execution

HAMILTON, Bermuda, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 28, 2023, at 8:30 a.m. Eastern Time to report its fourth quarter and full-year 2022 financial results and recent portfolio execution.

Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on February 28, 2023

Kiniksa did very well with arcalyst, buying low, selling well. However, its pipeline does not excite investors.

Kiniksa: Steady Progress With Arcalyst, But Still Pretty Unexciting

News for Kiniksa Pharmaceuticals Ltd Stock (KNSA)